scholarly journals Elevated Polyamines in Saliva of Pancreatic Cancer

2018 ◽  
Author(s):  
Yasutsugu Asai ◽  
Takao Itoi ◽  
Masahiro Sugimoto ◽  
Atsushi Sofuni ◽  
Takayoshi Tsuchiya ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Pancreatic Cancer ◽  
Capillary Electrophoresis ◽  
Chronic Pancreatitis ◽  
Screening Test ◽  
High Accuracy ◽  
The Other ◽  
Non Invasive ◽  
Accurate Detection ◽  
Significant Difference

Detection of pancreatic cancer (PC) at a resectable stage is still difficult because of the lack of accurate detection tests. The development of accurate biomarkers in low or non-invasive biofluids is essential to enable frequent tests, which would help increase the opportunity of PC detection in early stages. Polyamines have been reported as possible biomarkers in urine and saliva samples in various cancers. Here, we analyzed salivary metabolites, including polyamines, using capillary electrophoresis-mass spectrometry. Salivary samples were collected from patients with PC (n=39), chronic pancreatitis (CP, n=14) and controls (C, n=26). Polyamines, such as spermine, N1-acetylspermidine, and N1-acetylspermine, showed a significant difference between PC and C, and the combination of four metabolites including N1-acetylspermidine showed high accuracy in discriminating PC from the other two groups. These data showed the potential of saliva as a screening test for PC.

scholarly journals A Circulating Exosome RNA Signature Is a Potential Diagnostic Marker for Pancreatic Cancer, a Systematic Study

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2565
Author(s):  
Yixing Wu ◽  
Hongmei Zeng ◽  
Qing Yu ◽  
Huatian Huang ◽  
Beatrice Fervers ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Early Detection ◽  
Validation Dataset ◽  
Healthy Controls ◽  
Rna Seq ◽  
Healthy Individuals ◽  
Kras Mutations ◽  
Significant Difference ◽  
Rna Signature

Several exosome proteins, miRNAs and KRAS mutations have been investigated in the hope of carrying out the early detection of pancreatic cancer with high sensitivity and specificity, but they have proven to be insufficient. Exosome RNAs, however, have not been extensively evaluated in the diagnosis of pancreatic cancer. The purpose of this study was to investigate the potential of circulating exosome RNAs in pancreatic cancer detection. By retrieving RNA-seq data from publicly accessed databases, differential expression and random-effects meta-analyses were performed. The results showed that pancreatic cancer had a distinct circulating exosome RNA signature in healthy individuals, and that the top 10 candidate exosome RNAs could distinguish patients from healthy individuals with an area under the curve (AUC) of 1.0. Three (HIST2H2AA3, LUZP6 and HLA-DRA) of the 10 genes in exosomes had similar differential patterns to those in tumor tissues based on RNA-seq data. In the validation dataset, the levels of these three genes in exosomes displayed good performance in distinguishing cancer from both chronic pancreatitis (AUC = 0.815) and healthy controls (AUC = 0.8558), whereas a slight difference existed between chronic pancreatitis and healthy controls (AUC = 0.586). Of the three genes, the level of HIST2H2AA3 was positively associated with KRAS status. However, there was no significant difference in the levels of the three genes across the disease stages (stages I–IV). These findings indicate that circulating exosome RNAs have a potential early detection value in pancreatic cancer, and that a distinct exosome RNA signature exists in distinguishing pancreatic cancer from healthy individuals.

scholarly journals Validation of Urinary Charged Metabolite Profiles in Colorectal Cancer Using Capillary Electrophoresis-Mass Spectrometry

Metabolites ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 59
Author(s):  
Toru Sakurai ◽  
Kenji Katsumata ◽  
Ryutaro Udo ◽  
Tomoya Tago ◽  
Kenta Kasahara ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Capillary Electrophoresis ◽  
Healthy Controls ◽  
Discrimination Ability ◽  
Significant Difference ◽  
Metabolite Profiles ◽  
The Difference ◽  
Pathway Analyses ◽  
Higher Sensitivity ◽  
Capillary Electrophoresis Mass Spectrometry

This study aimed to validate and reanalyze urinary biomarkers for detecting colorectal cancers (CRCs). We previously conducted urinary metabolomic analyses using capillary electrophoresis-mass spectrometry and found a significant difference in various metabolites, especially polyamines, between patients with CRC and healthy controls (HC). We analyzed additional samples and confirmed consistency between the newly and previously analyzed data. In total, we included 36 HC, 34 adenoma (AD), and 214 CRC samples, which were used for subsequent analyses. Among the 132 quantified metabolites, 16 exhibited consistent differences in both datasets, which included polyamines, etc. Pathway analyses of the integrated data revealed significant differences in many metabolites, such as glutamine, and metabolites of the TCA and urea cycles. The discrimination ability of the combination of multiple metabolites among the three groups was evaluated, which yielded higher sensitivity than tumor markers. The Mann–Whitney test was employed to evaluate the prognosis predictivity of the assessed metabolites and the difference between the patients with or without recurrence, which yielded 16 significantly different metabolites. Among these 16 metabolites, 11 presented significant prognosis predictivity. These data indicated the potential of metabolite-based discrimination of patients with CRC and AD from HC and prognosis predictivity of the monitored metabolites.

Can IL-2R Alpha be a Valuable Marker along with Ca 19–9 in the Diagnosis of Chronic Pancreatitis and Pancreatic Cancer?

2004 ◽  
Vol 19 (3) ◽  
pp. 196-202
Author(s):  
B. Kayhan ◽  
B. Kayhan ◽  
M. Akdoğ;an
Keyword(s):  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Interleukin 2 ◽  
Carbohydrate Antigen ◽  
Control Group ◽  
Serum Samples ◽  
Cancer Group ◽  
Abdominal Symptoms ◽  
Significant Difference ◽  
Inflammatory Processes

Background Pancreatic cancer is characterized initially by non-specific abdominal symptoms followed by rapid tumor progression. Although chronic pancreatitis is a benign disorder, it can be one of the causative factors of pancreatic cancer. The level of the tumor marker carbohydrate antigen 19–9 (CA 19–9) in pancreatic cancer does not correlate with the stage of the neoplasm. Soluble interleukin 2 receptor (sIL-2R) is a cytokine that shows increased levels during some inflammatory processes and malignant disorders. Aim Our aim in this study was to investigate whether sIL-2Rα levels can be used in association with CA 19–9 in the early diagnosis of pancreatic cancer and chronic pancreatitis. Patients Serum samples were obtained from the blood of 21 pancreatic cancer patients without distant metastasis who were deemed inoperable, 16 chronic pancreatitis patients and 20 normal volunteers. Results We did not find any significant differences in CA 19–9 levels between normal controls and patients with chronic pancreatitis. There was a significant difference in the levels between the control group and the pancreatic cancer group (p=0.003) and between patients with chronic pancreatitis and those with pancreatic cancer (p=0.004). Although there was no significant difference in sIL-2Rα levels between the control group and the patient groups, we found a slight correlation between sIL-2Rα and CA 19–9 levels in the pancreatic cancer group (p=0.003, r=0.623) and a more marked correlation in the chronic pancreatitis group (p<0.01, r=0.751). Conclusion According to our results, sIL-2Rα alone is not a good candidate marker in the diagnosis of pancreatic cancer; it can, however, be used in association with CA 19–9 for this purpose.

scholarly journals Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles

Metabolomics ◽  
2009 ◽  
Vol 6 (1) ◽  
pp. 78-95 ◽  
Author(s):  
Masahiro Sugimoto ◽  
David T. Wong ◽  
Akiyoshi Hirayama ◽  
Tomoyoshi Soga ◽  
Masaru Tomita
Keyword(s):  
Mass Spectrometry ◽  
Pancreatic Cancer ◽  
Capillary Electrophoresis ◽  
Capillary Electrophoresis Mass Spectrometry

scholarly journals Biological diagnostic markers and pancreatic cancer risk factors in patients with chronic pancreatitis (literature review)

2020 ◽  
Vol 46 (1) ◽  
pp. 6-11
Author(s):  
A. A. Litvin ◽  
S. V. Korenev ◽  
E. N. Kolokoltseva ◽  
V. S. Denisyuk ◽  
S. B. Rumovskaya
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Serum Markers ◽  
Cancer Risk Factors ◽  
Non Invasive ◽  
Hereditary Risk ◽  
B Virus ◽  
Mutant Genes

Pancreatic cancer (PC) prevalence has steadily increased in recent years. It is untimely diagnosed due to prolonged asymptomatic course, minor changes in routine laboratory indices, lack of informative value of standard visualizing techniques. In this regard, attention is paid to determination of PC risk factors and establishment of biomarkers (diagnostic, prognostic, predictive) for pancreatic neoplastic transformation on the background of chronic pancreatitis. Non-inherited PC risk factors include old age, smoking, chronic pancreatitis, Helicobacter pylori/hepatitis B virus infection, obesity, diabetes mellitus. PC family history, family adenomatous polyposis, carriage of mutant genes (PRSS1, SPINK1, BRCA2) dominate among hereditary risk factors. Biomarkers can be used not only for early non-invasive diagnosis of PC, but also for differential diagnosis between chronic pancreatitis and PC. Sensitivity and specificity of various PC serum markers, such as CA19-9, PAM4, MIC-1, are analyzed in the article. It is possible to distinguish PC from autoimmune pancreatitis by determining the serum concentration of IgG4. In addition to blood serum, fecal masses (K-RAS, BMP3) and saliva (KRAS, MBD3L2, ACRV1 and DPM1) can be used to determine the potential markers of PC. New data of determination the fecal miRNAs as PC cancer biomarkers are presented, namely miR-21, miR-155 and miR-216. Majority of PC biomarkers have not been introduced into a routine clinical practice yet, and research on their informative value is ongoing.

scholarly journals Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis

Gut ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 128-137 ◽  
Author(s):  
Julia Mayerle ◽  
Holger Kalthoff ◽  
Regina Reszka ◽  
Beate Kamlage ◽  
Erik Peter ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma ◽  
Diagnostic Purpose ◽  
Training Set ◽  
Test Set ◽  
Increased Risk ◽  
Biomarker Signature

ObjectiveCurrent non-invasive diagnostic tests can distinguish between pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)) and chronic pancreatitis (CP) in only about two thirds of patients. We have searched for blood-derived metabolite biomarkers for this diagnostic purpose.DesignFor a case–control study in three tertiary referral centres, 914 subjects were prospectively recruited with PDAC (n=271), CP (n=282), liver cirrhosis (n=100) or healthy as well as non-pancreatic disease controls (n=261) in three consecutive studies. Metabolomic profiles of plasma and serum samples were generated from 477 metabolites identified by gas chromatography–mass spectrometry and liquid chromatography–tandem mass spectrometry.ResultsA biomarker signature (nine metabolites and additionally CA19-9) was identified for the differential diagnosis between PDAC and CP. The biomarker signature distinguished PDAC from CP in the training set with an area under the curve (AUC) of 0.96 (95% CI 0.93–0.98). The biomarker signature cut-off of 0.384 at 85% fixed specificity showed a sensitivity of 94.9% (95% CI 87.0%–97.0%). In the test set, an AUC of 0.94 (95% CI 0.91–0.97) and, using the same cut-off, a sensitivity of 89.9% (95% CI 81.0%–95.5%) and a specificity of 91.3% (95% CI 82.8%–96.4%) were achieved, successfully validating the biomarker signature.ConclusionsIn patients with CP with an increased risk for pancreatic cancer (cumulative incidence 1.95%), the performance of this biomarker signature results in a negative predictive value of 99.9% (95% CI 99.7%–99.9%) (training set) and 99.8% (95% CI 99.6%–99.9%) (test set). In one third of our patients, the clinical use of this biomarker signature would have improved diagnosis and treatment stratification in comparison to CA19-9.

scholarly journals Determination of DNA Damage in Floriculturists Exposed to Mixtures of Pesticides

2006 ◽  
Vol 2006 ◽  
pp. 1-12 ◽  
Author(s):  
J. Castillo-Cadena ◽  
L. E. Tenorio-Vieyra ◽  
A. I. Quintana-Carabia ◽  
M. M. García-Fabila ◽  
E. Ramírez-San Juan ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Dna Damage ◽  
Chronic Exposure ◽  
Preventive Measures ◽  
Exposed Group ◽  
The Other ◽  
Significant Difference ◽  
And Control

The aim of the study was to determine possible DNA damage in floriculturists chronically exposed to pesticides. Leukocytes from 52 workers, 46 environmentally exposed, and 38 control individuals were evaluated with the comet assay. Serum from all individuals was also analyzed for pesticides using gas chromatography coupled to mass spectrometry. A statistically significant difference in DNA fragmentation in the pesticide exposed group compared to the other two groups (P<.001) was found. No differences between environmentally exposed and control individuals were detected. The statistical analysis showed no significant correlation between DNA damage and sex, age, drinking or smoking habits, as well as years of exposure. One or more pesticides were detected in50%of the floriculturists, while in the rest of the individuals, a chemical related with the preparation of pesticides, such as additives, plasticizers, or solvents, was found. Our study shows that chronic exposure to pesticides produces DNA damage in floriculturists. It also suggests that this type of monitoring could be valuable in recommending preventive measures.

Sign in / Sign up

Export Citation Format

Share Document